EC approves Pfizer ’s acute lymphoblastic leukemia treatment Besponsa

The European Commission (EC) has approved Pfizer ’s Besponsa (inotuzumab ozogamicin) for the treatment of adults with relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukaemia (ALL) in the European Union (EU).
Source: Pharmaceutical Technology - Category: Pharmaceuticals Source Type: news